BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 2,121 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $79.91, for a total value of $169,489.11. Following the transaction, the executive vice president now directly owns 61,281 shares in the company, valued at approximately $4,896,964.71. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of BMRN opened at $79.25 on Friday. The stock has a fifty day moving average price of $76.67 and a two-hundred day moving average price of $98.44. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.34 and a current ratio of 3.26. BioMarin Pharmaceutical Inc. has a 52-week low of $67.10 and a 52-week high of $131.95. The company has a market cap of $14.37 billion, a price-to-earnings ratio of 120.08, a PEG ratio of 5.63 and a beta of 0.73.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.17. BioMarin Pharmaceutical had a return on equity of 4.37% and a net margin of 6.62%. The firm had revenue of $429.49 million during the quarter, compared to the consensus estimate of $418.02 million. As a group, research analysts predict that BioMarin Pharmaceutical Inc. will post 0.38 EPS for the current fiscal year.

BMRN has been the topic of a number of research analyst reports. BMO Capital Markets raised their target price on BioMarin Pharmaceutical from $94.00 to $108.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. SVB Leerink lowered their target price on BioMarin Pharmaceutical from $140.00 to $113.00 and set an “outperform” rating on the stock in a report on Wednesday, August 19th. BidaskClub lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Thursday, October 1st. Piper Sandler raised their target price on BioMarin Pharmaceutical from $120.00 to $133.00 in a report on Wednesday, August 5th. Finally, Morgan Stanley lowered their target price on BioMarin Pharmaceutical from $125.00 to $85.00 and set an “equal weight” rating on the stock in a report on Friday, August 21st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $120.12.

A number of institutional investors and hedge funds have recently modified their holdings of BMRN. Commonwealth Equity Services LLC raised its position in BioMarin Pharmaceutical by 13.7% in the 1st quarter. Commonwealth Equity Services LLC now owns 3,451 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 415 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of BioMarin Pharmaceutical by 2.7% during the first quarter. Victory Capital Management Inc. now owns 123,333 shares of the biotechnology company’s stock worth $10,422,000 after acquiring an additional 3,196 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of BioMarin Pharmaceutical by 4.2% during the first quarter. Principal Financial Group Inc. now owns 42,780 shares of the biotechnology company’s stock worth $3,615,000 after acquiring an additional 1,737 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of BioMarin Pharmaceutical during the first quarter worth $333,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in shares of BioMarin Pharmaceutical by 37.2% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,350 shares of the biotechnology company’s stock worth $452,000 after acquiring an additional 1,450 shares during the last quarter. Hedge funds and other institutional investors own 98.59% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Story: Oversold

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.